近日,国内GLP-1类创新减重药物玛仕度肽在中国超重或肥胖受试者中的Ⅲ期临床研究(GLORY-1)登上国际知名期刊《新英格兰医学杂志》,这是全球首个且唯一申报上市的胰高血糖素(GCG)/胰高血糖素样肽-1(GLP-1)双受体激动剂减重降糖药物的临床研究首次登上医学权威学术期刊。而玛仕度肽并非全球首个开展临床研究的双靶点GLP-1激动剂药物,GLORY-1为何能登上国际顶刊? 图片来源:《...
Source Link近日,国内GLP-1类创新减重药物玛仕度肽在中国超重或肥胖受试者中的Ⅲ期临床研究(GLORY-1)登上国际知名期刊《新英格兰医学杂志》,这是全球首个且唯一申报上市的胰高血糖素(GCG)/胰高血糖素样肽-1(GLP-1)双受体激动剂减重降糖药物的临床研究首次登上医学权威学术期刊。而玛仕度肽并非全球首个开展临床研究的双靶点GLP-1激动剂药物,GLORY-1为何能登上国际顶刊? 图片来源:《...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.